VCBeat Health Contact Us
Home Hansoh Pharmaceutical (03692.HK) Announces Class 1 New Drug HS-10516 Capsules Receives Clinical Trial Approval

Hansoh Pharmaceutical (03692.HK) Announces Class 1 New Drug HS-10516 Capsules Receives Clinical Trial Approval

Jun 13, 2023 17:03 CST Updated 17:03
Hansoh Pharma

Pharmaceutical Research, Production, and Sales

Hansoh Pharma (03692) announced that the Class 1 new drug "HS-10516 Capsule" (introduced as NKT2152) has received the clinical trial notification issued by the China National Medical Products Administration, intended for the treatment of renal cell carcinoma.